Cannabis & Treaty Scheduling archive.
In 2020, for the first time ever, Cannabis scheduling status within international law evolves. WHO’s 4-years assessment process of therapeutic value and harms related to Cannabis sativa L., repealing the 1950’s ban, is likely to change policies globally – to focus on medical access, health and Human Rights. This page compiles some of the work produced to impulse the review process and ensure the independence, objectivity, and comprehensiveness of the assessment.
Last update: May 4th, 2020.
On January 24th, 2019, the World Health Organization (WHO) released the final outcome of its scientific assessments of Cannabis sativa-based products and substances, following the reviews undertaken at the WHO’s Expert Committee on Drug Dependence 39th, 40th and 41st meetings. The very positive outcome (best result WHO could possibly come up with in the current context) acknowledges the medical benefits of Cannabis and cannabinoids, reintegrates them into pharmacopeias, balances harms, and de facto repeals the WHO position from 1954 according to which “there should be an
The international scheduling proposed by WHO provides with a highly simplified and normalized international control, as well as an increased possibility for countries to provide legal and safe access for medical use in a pragmatic, coherent, and rights-enhancing manner.
The final adoption of these recommendations by the UN Commission on Narcotic Drugs (CND) is expected for March 2020 during CND’s 63rd session.
Click here to unfold more background information
In November 2016, the World Health Organization (WHO) launched a process of scientific assessment of the uses (not only medical) and potential harms of the plant Cannabis sativa L. and its derivatives. The final outcome of the WHO will be recommendations to place Cannabis and its derivatives in the suitable “Schedules” of the International Drug Control Conventions. These schedules list all controlled drugs by their perceived level of harm and directly impacts the international law and regulation to be applied to the said drug. Part of the work of our team consisted in promoting a neutral, comprehensive and independent assessment, that recognizes and acknowledges both traditional knowledge and contemporary research on Cannabis (the plant) and cannabis (the “drug”).
Challenging and changing the current place of Cannabis/cannabis within the International Conventions’ Schedules (until now included in the lists binding Countries to prohibit the use of cannabis and to eradicate the cultivation of the Cannabis plant) will have profound effects worldwide, increasing room and opportunities for scientific research, but also medical access and supply. More broadly, it will ease off the pressure against cannabis policy reforms at the country level, and allow cannabis policies to be integrated and linked to national policies on health, education, economy or development.
The international obligations to prohibit cannabis – derived from the drug control Treaties (or Conventions) which consider cannabis as one of the drugs with the highest potential of harm and the least medical usefulness – have not evolved since 1961. This undue scheduling was slowly built with an obscure process that started in 1925, and that ended in 1961 with the inscription of Cannabis and its derivatives at the highest possible level of restrictive State control measures.
Unlike every other drug submitted to international restrictions, Cannabis has never been scientifically assessed between 1925 and 1961, when it was included at first in the international schedules of the treaties. It has neither been reassessed after the discovery in 1964 of tetrahydrocannabinol, or THC, the main active molecule of the Cannabis plant. Moreover since 1964, even though dozens of new clinical applications were evidenced by research, no further scientific review of the plant and its compounds was undertaken.
Since then, almost every single country has been following this scheduling, placing cannabis and Cannabis-based medicines and health products under the strictest national regulations, blocking availability and access for medical patients and researchers, making almost impossible legal production, trade, or quality certifications, and creating de facto an almost total prohibition of cannabis, thus generating countless collateral harms.
While the current classification of cannabis in the Treaties is, almost unbelievably, from an outdated and obscure evidentiary process conducted before 1961, no scientific evidence-based process has been led to assess cannabis and classify it in the right Schedule since that date.
“It is important to recognize the extreme complexity of international drug policy related to plant and substance scheduling, but also its primary and central role in the prohibition regime, and its impact on day-to-day practices and local policies.” – Michael Krawitz, FAAAT Global Policy Advisor.
The process of scientific assessment by the Expert Committee on Drug Dependence (ECDD), only one able to change the status of cannabis within the Treaties schedules, is a routine internal process of the World Health Organization. It has however been repeatedly blocked since the adoption in 1961 of the Single Convention on narcotic drugs, while it could and should have happened long ago.
In 2014, Michael Krawitz, Farid Ghehiouèche and Kenzi Riboulet Zemouli started to work together to act in favor of downgrading the level of control of Cannabis (and sometimes the associated prohibition) imposed to all countries by an international agreement dating 1961, and founding its roots in early XXth Century geopolitical arrangements more led by moral considerations than by evidence.
The problematic scheduling status of Cannabis was our focus. The international community had just outrageously broken its own rules to avoid changing the scheduling of THC, times were changing, and so were the officials and personnel of international institutions. The UNGASS 2016 was on the horizon and Uruguay had just lost his struggle against the rest of the planet by passing a downgraded legalization bill.
Our actions were tridirectional: past, present, and future. We started a comprehensive review of the archives and historical steps leading to the by-then scheduling status of Cannabis; we started mainstreaming the topic among United Nations stakeholders, decision-makers, researchers, civil society and the global cannabis community; and we launched a series of actions to ensure that the beginning of a process aiming to update the scheduling status of Cannabis would come as soon as possible.
We render part of our work on this website, briefing our fellow drug policy reform advocates and all interested parties about the ongoing and expected changes in that domain.
Blog posts & Press releases
PRESS RELEASE | 31st Jan. 2019 | Outcome of #ECDD41 on Cannabis. World Health Organization acknowledges medical use of Cannabis after 60 years of denial.
WHO finishes this week their scientific review of cannabis, THC, CBD extracts, etc. Their conclusions could change cannabis scheduling in the drug Treaties.
After thoroughly assessing Cannabis, THC and CBD in June, the WHO has just recognized its historical misjudgment that led to the placement of Cannabis medicines among heroin or fentanyl derivates, and will consider an international change of scheduling to adequate policies with evidence. #ECDD40
This week in Geneva for the first time ever, the WHO drugs committee has heard the voices of doctors, patients, and researchers, and started to weigh the harms and benefits of Cannabis neutrally.
FAAAT submitted a contribution to the post-UNGASS 2016 thematic debates organized by the UN Commission on Narcotic Drugs, on October 2016. This contribution has been posted online on the website of the UNODC and can be downloaded here.
Review Process and History of Cannabis scheduling.
The Crimson Digest, Volume 1.
Briefing on the international scientific assessment of cannabis: Processes, stakeholders and history.
Riboulet-Zemouli K. | FAAAT think & do tank, Geneva, November 2018. | ISBN 979-10-97087-06-7
Our contributions to the 41st ECDD meeting | November 2018
Our contribution to the 40th ECDD meeting | June 2018
ECDD40: Joint Civil Society statement on the Critical review of Cannabidiol and Pre-reviews of Cannabis, resin, extracts, tinctures and THC.
Joint civil society contribution to the 40th WHO Expert Committee on Drug Dependence evaluation of Cannabis and its related products and substances – June 4th, 2018.
Our contribution to the 39th ECDD meeting | November 2017
Understanding the Schedules of the 1961 and 1971 Conventions.
Members of the ECDD.
Timeline of the review process.
Below is the timeline of the different part of the review process of Cannabis and Cannabis-related products and substances.
Below is the agenda & timeline of the review process, and the actions undertaken by our teams. Click on the red boxes to display detailed information about each step.
[Next step] March 2020 | CND63 | Vote on the ECDD recommendations
March 2019 | CND62 | Delay of the vote on ECDD outcome recommendations
The Commission on Narcotic Drugs adopted, by consensus, a decision to postpone sine die the vote on the WHO Expert Committee’s final recommendations. While the vote was initially expected to take place in December, it is now likely that the Commission only takes action on the WHO recommendations in March 2020 during the 63rd Commission on Narcotic Drugs.
December 2018 | CND61-REC | Partial outcome of ECDD41 & International Cannabis Policy Conference
During the reconvened session of the 61st Commission on Narcotic Drugs meeting, the WHO was supposed to present to
The International Cannabis Policy Conference started simultaneously and explored the policy and regulatory consequences of the WHO outcome recommendations, as well as the future of Cannabis policies globally and their link with Sustainable Development.
November 2018 | ECDD41 | 41st meeting of the WHO’s Expert Committee on Drug dependence
July 2018 | ECDD40 | Outcome
On July 23rd, the Director-General of WHO Tedros Adhanom Ghebreyesus (known as Dr. Tedros), sent a Note Verbale to the Secretary-General of the United Nations, António Guterres. The purpose was to inform him of the outcome of the 40th meeting of the Expert Committee on Drug Dependence (ECDD) held June 2018, that was dedicated to the scientific assessment of Cannabis and its related products. Guterres forwarded the letter to all countries Member of the 1961 and 1971 Conventions on narcotic drugs and psychotropic substances.
A big part of our remarks (delivered in our Joint Statement to the Experts) was acknowledged by the WHO, and most of the weaknesses and bias in the preparation process seem to have been overcome… To be confirmed at the 41st ECDD (12-16 November 2018) where the final part of this assessment will be done.
A very positive preliminary outcome was issued for “Cannabis and Cannabis resin”, as the Experts acknowledged that withdrawing the Cannabis plant from the “prohibition schedule”, (Schedule IV of the 1961 Convention) should be at the agenda of the 41st ECDD meeting, for a final decision going in that direction.
The Experts also recognized the incoherence in the terminology and taxonomy applied to the products included in the category “extracts and tinctures”.
Also, CBD was recommended for non-inclusion in the Treaties’s schedules, even though the journey is not over and the actual extracts of the Cannabis plant that are CBD-rich will be reviewed again as “extracts and tinctures of Cannabis”.
The next step will be the 41st ECDD from 12th to 16th November 2018, where the final part of the assessment (Critical review) will be undertaken by the Experts. They are likely to issue recommendations for lowering the scheduling status of Cannabis, Cannabis resin, Cannabis extracts and tinctures (including CBD-rich extracts), THC and THC isomers.
The final step is expected for March 2019, when the UN Commission on Narcotic Drugs will adopt or reject the recommendations of the WHO ECDD.
Resume of the final outcome for CBD, and preliminary outcomes for Extracts, tinctures, resin and herbal Cannabis:
June 2018 | ECDD40 | Special ECDD meeting for the review of Cannabis-related products
In June 2018 took place the 40th meeting of the WHO ECDD, special meeting dedicated to pre-reviews of Cannabis-related substances and the Critical review of pure CBD.
On the occasion of the 40th meeting of the WHO Expert Committee on Drug Dependence (ECDD) dedicated to the scientific assessment of Cannabis and its related products, we delivered a Joint Statement to the Experts, underlining gross bias in the preparation process of the meeting.
We coordinated two main actions:
- Written contribution from Civil Society organizations, experts, academics as well as patients and affected populations.
150+ civil society organizations from all continents endorsed a written contribution, pointing out and examining in detail the bias that undermined the review process. Among the signee organizations are scientists, doctors, human rights, affected populations, patients, students, users or groups of healthcare and dependence professionals.
They come from Afghanistan, Argentina, Australia, Austria, Belgium, Bolivia, Canada, Chile, Colombia, Costa Rica, Czech Republic, El Salvador, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Jamaica, Mexico, Paraguay, Peru, Portugal, Santa Lucia, South Africa, Spain, Switzerland, the Netherlands, Trinidad and Tobago, the United Kingdom, Uruguay, United States of America and Zimbabwe.
- In-person and video presentations from Civil Society representatives during the ECDD40 Open Session.
Beyond the regrettable bias pointed out in the Written Contribution (see above), the Experts were given a broad and complete overview of the challenges, threats or human rights violations provoked by the current regulatory framework surrounding Cannabis.
Among the stakeholders present at the Monday Open Session, all pointed out the barriers to access for therapeutical purposes or the disproportionate impact of criminal justice measures that derivates from the current Scheduling, particularly over minorities and women. However, series of technical issues made difficult a real concentration of the Experts on some statements, betraying the known heaviness of the “Organization” and its difficulties in preparing an event of such historical importance.
“On the year of its 70th birthday, the World Health Organization (WHO) is finally taking steps to repair an injustice that it co-created: the affirmation that Cannabis had no medical value, based on biased scientific processes, as a ground for the global prohibition of traditional and recreational uses of Cannabis, as well as severe restrictions to medical access and research.”
Last June in Geneva, for the first time ever, the WHO listened to the voices of doctors, patients, and researchers, and started to analyze and weigh the harms and benefits of Cannabis for health neutrally. Their conclusions are likely to change international law and impact home policies globally.
Learn more in our post: 40th ECDD meeting in Geneva: a pivotal moment for global Cannabis policies.
We also issued a press release in 3 languages about the Open Session:
May 2018 | WHA71 | General Assembly of the WHO
March 2018 | CND61 | United Nations specialized drugs Commission
December 2017 | CND60-REC | United Nations specialized drugs Commission, Reconvened meeting
December 2017 | ECDD39 | Outcome
November 2017 | ECDD39 | Regular meeting including Pre-review of CBD
In November 2017, as the Expert Committee was starting the review process with the Pre-review of Cannabidiol, we joined efforts with the European Industrial Hemp Association (EIHA) to present a joint statement on this occasion, both orally and in an extended written version (Main authors: Boris Baňas, Dr. Bernard Beitzke, Dr. Giuseppe Cannazza, Michael Carus, Hana Gabrielová, Farid Ghehioueche, Kerstin Iffl and, Michael Krawitz, Daniel Kruse, Eberhard Pirich, M.D., Kenzi Riboulet Zemouli).
Our conclusion stated:
CBD is a safe to use substance that is beneficial to human health and public welfare and has numerous applications in industry and nutrition, cosmetics as well as health and wellbeing products, besides its promising benefits in diverse indications such as reducing anxiety or helping people to quit smoking.
Applying the measures laid down in the international drug control treaties to Cannabidiol would severely restrict its availability for the non-problematic consumers of CBD and CBD-related products, as well as undermining safe access for many patients who already profit from CBD’s manifold health-related and homeostasis-supporting effects. In addition to diminishing public welfare, employment in the blooming hemp industry would be actively destroyed, and the already existing and regulated market of non-therapeutical hemp-based products would shrink significantly, despite just having experienced a rebirth after almost a Century of oppression.
Finally, Cannabidiol does not fit any of the requirements or criteria for inclusion in the international drug control treaty schedules, and it lacks the properties usually attributed to psychotropic substances or narcotic drugs.
Therefore we strongly urge the WHO to clearly recommend the exclusion of Cannabidiol from the scope of the international control measures, and reaffirm its unbelonging to the lists of internationally controlled substances.
- Joint EIHA – FAAAT contribution to the 39th ECDD evaluation of Cannabidiol
- Press release EIHA-FAAAT on the outcome of the CBD Pre-review.
March 2018 | CND60-INT | United Nations specialized drugs Commission, Intersessional meeting
March 2018 | CND60 | United Nations specialized drugs Commission
December 2016 | CND59-REC | United Nations specialized drugs Commission, Reconvened meeting
November 2016 | ECDD38 | Regular meeting, where the Review process was launched
- Presence at the ECDD38
In November 2016, we registered again to attend the 38th ECDD, although the security service of the WHO arbitrarily detained us and difficulted our mission.
- Actions undertaken prior to ECDD38
After having gathered for years an important number of elements of evidence supporting the obligation to start the review for the WHO, we combined these to other previous declarations of the UN Commission on Narcotic Drugs (CND) and the International Narcotics Control Board (INCB) supporting our request, and we wrote a letter to the by-then WHO Director-General Dr. Margaret Chan – sent again by hundreds of scientists and political figures.
On three consecutive occasions before November 2016, the WHO eluded the review of cannabis by organizing pointless “update” meetings, with no procedural value in the scheduling process. In November 2016 however, the WHO finally decided to begin the review process for cannabis, under different items, starting with cannabidiol (CBD), and convening a special ECDD meeting to Pre-review all other by-products of the Cannabis plant.
October 2016 | CND59-INT | United Nations specialized drugs Commission, Intersessional meeting
Reassessing substances: one proposed reading of the UNGASS 2016 outcome document.
Contribution to the post-UNGASS 2016 thematic debatesorganized by the UN Commission on Narcotic Drugs, on October 10th, 11th, 27th and 28th 2016. This contribution has been posted online on the website of the UNODC and can be downloaded on our own website (only in English).
May-November 2016 | Researches in the archives of United Nations and League of Nations
May 2016 | WHA69 | General Assembly of the WHO
- lobby outreach
- work with a country delegation that formulated orally in plenary the ask for the launch of the review process of Cannabis by the World Health Organization.
- diffusion of a Memo for Country delegations at the 69th World Health Assembly, providing precisions and details about the review process, and evoking ways forward for countries to get involved in the assessment and review process just about to be launched by the World Health Organization
- diffusion of a Civil Society declaration on behalf of the International Medical Cannabis Patients Coalition (IMCPC):
CIVIL SOCIETY STATEMENT: UNGASS 2016 OUTCOME DECLARATION AND THE CRITICAL REVIEW OF CANNABIS & CANNABIS RESIN
The public health dimension of the world drug problem has been widely debated during the special session of the United Nations General Assembly on the world drug problem (UNGASS) held past April, and along the preparation process held in Vienna since 2014. We note with satisfaction that the outcome declaration adopted at this Special Session recommends a renewed, balanced and scientific evidence-based approach towards the international drug control regime, while reaffirming the treaty-mandated role of WHO.
April 2016 | UNGASS | United Nations General Assembly Special Session on the 'World Drug Problem'
The supreme organ of the United Nations, its General Assembly, held a Special Session focused on drugs (called UNGASS 2016, for United Nations General Assembly Special Session).
Among other positive elements included in the outcome document, the countries agreed on the need of renewing, balancing and basing on scientific evidence the approaches to the international scheduling system, and reaffirmed the role of the WHO. They also resolved to “[support] scientific evidence-based review and scheduling of the most prevalent, persistent and harmful substances” and called for “informed and coordinated scheduling decisions.”.
For more information, see our Official contribution to the Commission on Narcotic Drugs about UNGASS 2016 and its links with the Cannabis review process and our Contribution to the 69th World Health Assembly.
March 2016 | CND59 | United Nations specialized drugs Commission
December 2015 | CND58-REC | United Nations specialized drugs Commission, Reconvened meeting
November 2015 | ECDD37 | Regular meeting
We started attending the ECDD meetings, on their 37th session. Cannabis was on the agenda as an “update”, which main document had been drafted by the controversed Pr. Bertha K. Madras. Our team member Michael Krawitz read a statement.
- WHO website for ECDD37
- Bertha Madras’ update on Cannabis for ECDD37
- Michael Krawitz’s statement at ECDD37 Open Session. Note: the statement uploaded online by the WHO has been censored and does not includes all the commentes regarding the inconsistency of nominating Bertha K. Madras for the update report.
March 2015 | CND58 | United Nations specialized drugs Commission
March 2014 | CND57 | United Nations specialized drugs Commission
Until 2014, a review process for THC had been started at the WHO, thought to help secure access to some basic cannabis medicines, but also as a first step to try out the reaction of the countries. That process was brutally stopped by the countries through the UN Commission on Narcotic Drugs (CND), and the WHO abandoned the idea. At this moment, our team started to gather energy in view of a new start for the WHO assessment process, this time not only for THC, but for the whole plant.